Clinical Trials Logo

Clinical Trial Summary

The primary objective of the study is to determine whether armodafinil treatment is more effective than placebo treatment in patients with excessive sleepiness associated with shift work disorder (SWD) by measuring improved clinical condition late in the shift, including the commute home.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01080807
Study type Interventional
Source Teva Pharmaceutical Industries
Contact
Status Completed
Phase Phase 4
Start date March 2010
Completion date October 2010

See also
  Status Clinical Trial Phase
Recruiting NCT01766323 - Palliative Morphine With or Without Concurrent Modafinil Phase 3
Completed NCT00758498 - Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder Phase 3
Completed NCT00711516 - Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance Phase 4
Completed NCT00174174 - Provigil (Modafinil) Study by Taiwan Biotech Co. N/A
Terminated NCT04618263 - Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers Phase 1
Completed NCT00080288 - Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD Phase 3
Completed NCT02806908 - Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy Phase 2
Completed NCT02806895 - Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA Phase 2
Recruiting NCT04788953 - Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder Phase 4
Completed NCT03881852 - Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) Phase 2
Completed NCT03037203 - A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness Phase 2
Completed NCT05008341 - Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration Phase 1